Skip to main content

Advertisement

Table 2 Clinical response to ipilimumab 10 mg/kg

From: Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme

Response Responses at the end of induction, week 12 (N = 69)* n (%) Responses across all treatment phases (N = 69)* n (%)
CR 1 (1.5) 3 (4.3)
PR 5 (7.2) 6 (8.7)
SD 15 (21.7) 13 (18.9)
PD 48 (69.6) 47 (68.1)
ORR 6 (8.7) 9 (13.0)
DCR N/A 22 (31.9)
  1. * Evaluable patients.
  2. By definition, SD must be of at least 24 weeks duration to be included in the disease control category.
  3. CR complete response, DCR disease control rate (PR + CR + SD), N/A not applicable, ORR objective response rate, PD progressive disease, PR partial response, SD stable disease.